Effect of niridazole in cellular immunity in vivo and in vitro.
The influence of niridazole, an anti-helminthic drug, on cell-mediated immune responses was investigated. Allograft rejection in mice as well as the in vitro induction of cytotoxic T lymphocytes (CTL) against murine alloantigen were used as the test system. Repeated daily oral treatment of host mice with niridazole (100 mg/kg) prior to and during allotransplantation resulte in the postponement of graft rejection, inducing a transitory functional state of allograft tolerance. The time interval between the termination of niridazole administration and onset of graft rejection was estimated to be 5-7 days. In order to test the effect of niridazole or its derivatives on the in vitro induction of alloreactive CTL, the serum or urine of mice which were treated with niridazole were added to the cultures, instead of adding niridazole directly to the cultures. Such serum and urine were found to be inhibitory for in vitro induction of CTL. The serum and urine had no effect on the effector phase of CTL.
D000284:Administration, Oral; D000818:Animals; D003602:Cytotoxicity, Immunologic; D006084:Graft Rejection / Q000187:drug effects; D007111:Immunity, Cellular / Q000187:drug effects*; D007165:Immunosuppression Therapy; D007519:Isoantigens; D051379:Mice; D008815:Mice, Inbred Strains; D009560:Niridazole / Q000494:pharmacology*; D016038:Skin Transplantation; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D014184:Transplantation, Homologous
D007519:Isoantigens; D009560:Niridazole